News >

Avelumab Misses Primary Endpoints in Phase III Ovarian Cancer Trial

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 19, 2018

Alfred Sackeyfio
Avelumab (Bavencio) alone or in combination with pegylated liposomal doxorubicin (PLD) did not induce a statistically significant improvement in overall survival (OS) or progression-free survival (PFS) versus PLD alone in patients with platinum–resistant/refractory ovarian cancer, missing the primary endpoints of the phase III JAVELIN Ovarian 200 trial.

Moreover, JAVELIN Ovarian PARP 100 (NCT03642132) is an open-label, multicenter, phase III study randomizing patients with previously untreated advanced ovarian cancer to avelumab plus platinum-based chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib (Talzenna); chemotherapy followed by maintenance therapy with talazoparib; or chemotherapy plus bevacizumab (Avastin), followed by bevacizumab maintenance.
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer. Merck KGaA and Pfizer. Published November 19, 2018.. Accessed November 19, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication